WFH Cornerstone Initiative: Rwanda Marks 3 Years of Participation
The World Federation of Hemophilia (WFH) shared a proud post on X:
”The WFH recently visited our NMO in Rwanda, the Rwanda Fraternity Against Hemophilia (RFH), to meet with the new board and discuss good governance, bleeding disorders, and outreach strategies. This marks year 3 of their participation in the WFH Cornerstone Initiative.”
The World Federation of Hemophilia (WFH) recently visited the Rwanda Fraternity Against Hemophilia (RFH), its National Member Organization (NMO), as part of ongoing collaboration under the WFH Cornerstone Initiative.
Now in its third year of participation, RFH welcomed the WFH team to engage in discussions with the newly appointed board.
The visit focused on strengthening governance practices, improving national outreach, and addressing current challenges in bleeding disorder care across Rwanda.
This partnership underscores the continued commitment to building sustainable, patient-centered care systems in low-resource settings.
All the latest news in the World of Bleeding Disorders featured in Hemostasis Today.
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 07:11Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
-
Sep 8, 2025, 06:54Indraneel Deshmukh Presenting Posters on Polycytemia Vera and More at SOHO 2025
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 8, 2025, 06:19Maria Abbattista: From Combined Hormonal Contraceptives to Cerebral Vein Thrombosis
-
Sep 8, 2025, 06:12David Smadja: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress